Support Sight in the News

New Treatment for AMD Accepted for FDA Priority Review

February 23, 2023 at 7:00 AM EST AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, [...]

By |2023-03-07T21:55:40+00:00March 7th, 2023|

Next Stop: AMD Central

Dawn Prall and Joshua Dunaief discuss AMD Central, a new site for people living with the condition Recently, I talked to Dawn Prall, founder and executive director of The SupportSight Foundation, and Joshua L. Dunaief, Adele Niessen Professor of Ophthalmology [...]

By |2021-09-17T17:50:12+00:00September 17th, 2021|

New Website for People Impacted by Age-Related Macular Degeneration Launched by Patient Advocacy Groups provides access to resources for patients and caregivers in one location AMD Central is a collaboration between the American Macular Degeneration Foundation, BrightFocus Foundation, MD Support, Prevent Blindness and The SupportSight Foundation BALA CYNWYD, Penn., March 25, 2021 /PRNewswire/ -- The [...]

By |2021-03-25T18:51:42+00:00March 25th, 2021|
Go to Top